85 related articles for article (PubMed ID: 38560203)
1. How selecting best upfront therapy for metastatic disease?-Focus on ROS1-rearranged disease.
Landi L; Cappuzzo F
Transl Lung Cancer Res; 2020 Dec; 9(6):2686-2695. PubMed ID: 33489827
[TBL] [Abstract][Full Text] [Related]
2. Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.
Morris TA; Khoo C; Solomon BJ
Drugs; 2019 Aug; 79(12):1277-1286. PubMed ID: 31313100
[TBL] [Abstract][Full Text] [Related]
3. Lung adenocarcinoma patients with
Peng Y; Ernani V; Liu D; Guo Q; Hopps M; Cappelleri JC; Gupta R; de Andrade M; Chen J; Yi ES; Yang P
Heliyon; 2024 Apr; 10(7):e28285. PubMed ID: 38560203
[TBL] [Abstract][Full Text] [Related]
4. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
[TBL] [Abstract][Full Text] [Related]
5. Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
Sehgal K; Piper-Vallillo AJ; Viray H; Khan AM; Rangachari D; Costa DB
Precis Cancer Med; 2020 Jun; 3():. PubMed ID: 32776005
[No Abstract] [Full Text] [Related]
6. ROS1 rearrangements define a unique molecular class of lung cancers.
Bergethon K; Shaw AT; Ou SH; Katayama R; Lovly CM; McDonald NT; Massion PP; Siwak-Tapp C; Gonzalez A; Fang R; Mark EJ; Batten JM; Chen H; Wilner KD; Kwak EL; Clark JW; Carbone DP; Ji H; Engelman JA; Mino-Kenudson M; Pao W; Iafrate AJ
J Clin Oncol; 2012 Mar; 30(8):863-70. PubMed ID: 22215748
[TBL] [Abstract][Full Text] [Related]
7. Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib.
De Giglio A; Lamberti G; Facchinetti F; Genova C; Andrini E; Dal Bello MG; Tiseo M; Metro G; Chiari R; Ricciuti B
Clin Lung Cancer; 2020 Sep; 21(5):e478-e487. PubMed ID: 32409267
[TBL] [Abstract][Full Text] [Related]
8. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.
Kim MH; Shim HS; Kang DR; Jung JY; Lee CY; Kim DJ; Lee JG; Bae MK; Kim HR; Lim SM; Kim EY; Park JS; Chung KY; Kim HJ; Kim JH; Cho BC
Lung Cancer; 2014 Mar; 83(3):389-95. PubMed ID: 24462463
[TBL] [Abstract][Full Text] [Related]
9. Real-world treatment patterns and survival of patients with ROS1 rearranged stage IV non-squamous NSCLC in the Netherlands.
Ten Berge DMHJ; Damhuis RAM; Aerts JGJV; Dingemans AC
Lung Cancer; 2023 Jul; 181():107253. PubMed ID: 37236088
[TBL] [Abstract][Full Text] [Related]
10. NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.
Ettinger DS; Wood DE; Aisner DL; Akerley W; Bauman JR; Bharat A; Bruno DS; Chang JY; Chirieac LR; DeCamp M; Dilling TJ; Dowell J; Durm GA; Gettinger S; Grotz TE; Gubens MA; Hegde A; Lackner RP; Lanuti M; Lin J; Loo BW; Lovly CM; Maldonado F; Massarelli E; Morgensztern D; Ng T; Otterson GA; Patel SP; Patil T; Polanco PM; Riely GJ; Riess J; Schild SE; Shapiro TA; Singh AP; Stevenson J; Tam A; Tanvetyanon T; Yanagawa J; Yang SC; Yau E; Gregory KM; Hughes M
J Natl Compr Canc Netw; 2023 Apr; 21(4):340-350. PubMed ID: 37015337
[TBL] [Abstract][Full Text] [Related]
11. Cancer statistics, 2023.
Siegel RL; Miller KD; Wagle NS; Jemal A
CA Cancer J Clin; 2023 Jan; 73(1):17-48. PubMed ID: 36633525
[TBL] [Abstract][Full Text] [Related]
12. Comparative Microbiomics Analysis of Antimicrobial Antibody Response between Patients with Lung Cancer and Control Subjects with Benign Pulmonary Nodules.
Shome M; Gao W; Engelbrektson A; Song L; Williams S; Murugan V; Park JG; Chung Y; LaBaer J; Qiu J
Cancer Epidemiol Biomarkers Prev; 2023 Apr; 32(4):496-504. PubMed ID: 36066883
[TBL] [Abstract][Full Text] [Related]
13. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics.
Provencio M; Cobo M; Rodriguez-Abreu D; Calvo V; Carcereny E; Cantero A; Bernabé R; Benitez G; Castro RL; Massutí B; Del Barco E; García Campelo R; Guirado M; Camps C; Ortega AL; González Larriba JL; Sánchez A; Casal J; Sala MA; Juan-Vidal O; Bosch-Barrera J; Oramas J; Dómine M; Trigo JM; Blanco R; Calzas J; Morilla I; Padilla A; Pimentao J; Sousa PA; Torrente M
BMC Cancer; 2022 Jul; 22(1):732. PubMed ID: 35790916
[TBL] [Abstract][Full Text] [Related]
14. Indoor Radon Exposure and COPD, Synergic Association? A Multicentric, Hospital-Based Case-Control Study in a Radon-Prone Area.
Ruano-Ravina A; Cameselle-Lago C; Torres-Durán M; Pando-Sandoval A; Dacal-Quintas R; Valdés-Cuadrado L; Hernández-Hernández J; Consuegra-Vanegas A; Tenes-Mayén JA; Varela-Lema L; Fernández-Villar A; Barros-Dios JM; Pérez-Ríos M
Arch Bronconeumol; 2021 Oct; 57(10):630-636. PubMed ID: 35699045
[TBL] [Abstract][Full Text] [Related]
15. Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology.
Adib E; Nassar AH; Abou Alaiwi S; Groha S; Akl EW; Sholl LM; Michael KS; Awad MM; Jӓnne PA; Gusev A; Kwiatkowski DJ
Genome Med; 2022 Apr; 14(1):39. PubMed ID: 35428358
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
